# Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption

> **NCT03710889** · PHASE3 · COMPLETED · sponsor: **Radius Health, Inc.** · enrollment: 23 (actual)

## Conditions studied

- Osteoporosis, Postmenopausal
- Osteoporosis
- Osteoporosis Vertebral
- Osteoporosis Risk
- Osteoporosis Fracture
- Osteoporosis Localized to Spine
- Osteoporosis, Age-Related
- Osteoporosis Senile
- Osteoporosis of Vertebrae

## Interventions

- **DRUG:** Abaloparatide

## Key facts

- **NCT ID:** NCT03710889
- **Lead sponsor:** Radius Health, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-20
- **Primary completion:** 2020-07-15
- **Final completion:** 2020-07-15
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2021-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03710889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03710889, "Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03710889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*